FUJIFILM América Latina
  • Inicio
  • Tecnologías
  • Medwork
  • Productos
    • Sistemas de Endoscopia
    • Fujifilm Accesorios
  • Distribuidores
  • Noticias y Eventos
  • Sobre Fujifilm
  • Soporte y Contacto
Select Page

Anti-influenza drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients

TOKYO — FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced today that primary endpoint has been met in phase III clinical trial of “Avigan Tablet” (generic name: favipiravir, “Avigan”) conducted in Japan for patients with novel coronavirus infections (hereinafter “COVID-19”). The efficacy primary endpoint is time to negative conversion of detectable SARS-CoV 2 viral RNA in the RT-PCR assays, and to alleviation of symptoms (body temperature, oxygen saturation and chest images).

FUJIFILM Toyama Chemical began a phase III clinical trial of Avigan in Japan in March 2020, for COVID-19 patients with non-severe pneumonia. The company conducted randomized, placebo-controlled, single-blind comparative study*1 to evaluate the efficacy and safety of Avigan.

The median value of primary endpoints, using 156 individuals as analysis targets, were 11.9 days for the Avigan group and 14.7 days for the placebo group. FUJIFILM Toyama Chemical confirmed, with a statistically significant difference (p value = 0.0136), that the administration of Avigan to COVID-19 patients with non-serious pneumonia demonstrates shorter time to resolution. The adjusted hazard ratio*2 showed 1.593 (95% confidence interval of 1.024 –2.479). No new safety concerns were noted in this trial.

FUJIFILM Toyama Chemical will conduct a detailed analysis of the data obtained in this trial, and will work to file Application for Partial Changes to include the additional indication in as early as October.

Approved for manufacture and sale in Japan as an influenza antiviral drug, Avigan, selectively inhibits RNA polymerase necessary for influenza virus replication. Due to this mechanism of action, it is expected that Avigan may have an antiviral effect on the new coronavirus, as they are RNA viruses of the same type as influenza viruses.

To meet the requests of the Japanese government to increase stockpiles of Avigan, and by other countries to supply the drug, the Fujifilm Group has been working to increase production of Avigan in collaboration with strategic partners. The Fujifilm Group will work to deliver the treatment drug to COVID-19 patients as soon as possible, and contribute to ending the spread of COVID-19.

*1 A trial in which the subjects are randomly allocated to a group receiving the actual drug or a group receiving a placebo, and a comparative investigation is made without informing the subjects about the drugs that had been allocated to them. In this trial, a comparison was made by administering Avigan and a placebo to the subjects, in addition to standard treatment.

*2 An indicator showing the relative risk of event occurrence by comparison is called a hazard ratio, and a ratio that adjusted the differences in background between the groups compared is called an adjusted hazard ratio. The hazard ratio used in this trial indicates the possibility of symptom relief and virologic responses turning negative. If the hazard ratio exceeds 1, administration of Avigan is judged to be more favorable.

® Tablets>
An anti-influenza drug developed by FUJIFILM Toyama Chemical that obtained domestic manufacturing and marketing approval in March 2014 with the treatment of new or reemerging influenza as the indication. The Japanese government has already stockpiled Avigan in preparation for the outbreak of the novel influenza.

 

 

 

For inquiries about this media release, please contact:
<Media>
FUJIFILM Holdings Corporation,
Corporate Communications Division, PR Group
Phone: +81-3-6271-2000

###

Política de privacidad      Condiciones de uso

© FUJIFILM Corporation
Cookies are important to the proper functioning of a site. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to optimize site functionality and deliver content tailored to your interest.
By continuing to use this site you are giving us your consent to do this. For more information you can read our Privacy Policy. Accept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT